Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of human hepatoma cells orthotopically implanted in nude rats

Cancer Science

Volumn 100, Issue 1, 2009, Pages 189-194

  Hanada, Mitsuharu ^a   Baba, Akemi ^a   Tsutsumishita, Yasuyuki ^a   Noguchi, Toshihiro ^a   Yamaoka, Takashi ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; IODINATED POPPYSEED OIL; MIRIPLATIN; PLATINUM COMPLEX; SM 11355; UNCLASSIFIED DRUG; ZINOSTATIN MALEIC ACID STYRENE COPOLYMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CHEMOEMBOLIZATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; NONHUMAN; NUDE RAT; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; DNA ADDUCTS; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; IODIZED OIL; LIVER NEOPLASMS, EXPERIMENTAL; LYMPHOGRAPHY; NEOPLASM TRANSPLANTATION; ORGANOPLATINUM COMPOUNDS; RATS; RATS, NUDE; TRANSPLANTATION, HETEROLOGOUS;

EID: 58149312589     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.01010.x     Document Type: Article

References (29)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-17.
2. Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001; 35: 421-30.
3. Llovet JM, Beaugrand M. Hepatocellular carcinoma. J Hepatol 2003; 38: S136-49.
4. Lo CM, Nygan H, Tso WK et al. Randomized controlled trial of transarterial Lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatol 2002; 35: 1164-71.
5. Llovet JM, Real MI, Montaña X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomized controlled trial. Lancet 2002; 359: 1734-9.
6. Mann JD. Alterations in the vasculature of the diseased liver. Gastroenterol 1953; 25: 540-6.
7. Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954; 30: 969-77.
8. Nilsson LAV, Zettergren L. Blood supply and vascular pattern of induced primary hepatic carcinoma in rats. Acta Path Microbiol Scand 1967; 71: 179-86.
9. Nakakuma K, Tashiro S, Hiraoka T et al. Studies on anticancer treatment with an oily anticancer drug injected into the ligated feeding hepatic artery for liver cancer. Cancer 1983; 52: 2193-200.
10. Nakakuma K, Tashiro S, Hiraoka T, Ogata K, Ootsuka K. Hepatocellular carcinoma and metastatic cancer detected by iodized oil. Radiol 1985; 154: 15-7.
11. Yumoto Y, Jinno K, Tokuyama K et al. Hepatocellular carcinoma detected by iodized oil. Radiol 1985; 154: 19-24.
12. Kan Z. Dynamic study of iodized oil in the liver and blood supply to hepatic tumors: An experimental investigation in several animal species. Acta Radiol 1996; 408: 1-25.
13. Maeda S, Shibata J, Fijiyama S et al. Long-term follow-up of hepatic arterial chemoembolization with cisplatin suspended in iodized oil for hepatocellular carcinoma. Hepato-Gastroenterol 2003; 50: 809-13.
14. Kishimoto S, Miyazawa K, Fukushima S, Takeuchi Y. In vitro antitumor activity, intracellular accumulation, and DNA adduct formation of cis -[(1R, 2R)-1,2-Cyclohexanediamine-N,N')bis(myristato)]Platinum (II) suspended in lipiodol. Jpn J Cancer Res 2000; 91: 99-104.
15. Kishimoto S, Miyazawa K, Terakawa Y et al. Cytotoxicity of cis- [(1 R, 2R)-1,2-cyclohexanediamine-N,N ')bis(myristato)]platinum (II) suspended in lipiodol in a newly established cisplatin-resistant rat hepatoma cell line. Jpn J Cancer Res 2000; 91: 1326-32.
16. Kishimoto S, Fukui M, Fukushima S, Nakano M. Application of a lipophilic platinum derivative contained in an oily lymphographic agent to intra-hepatic arterial chemotherapy. Reg Cancer Treat 1992; 1-2: 25-9.
17. Kishimoto S, Noguchi T, Yamaoka T, Fukushima S, Takeuchi Y. Antitumor effects of a novel lipophilic platinum complex (SM-11355) against a slowly-growing rat hepatic tumor after intra-hepatic arterial administration. Biol Pharm Bull 2000; 23: 344-8.
18. Ono Y, Yoshioka H, Ohkusa A et al. The effect of liposoluble cis-platinum (II) complex administered via hepatic artery on rat hepatic carcinoma. J Jpn Soc Cancer Ther 1992; 27: 49-58.
19. Fujiyama S, Shibata J, Maeda S et al. Phase I clinical study of a novel lipophilic platinum complex (SM-11355) in patients with hepatocellular carcinoma refractory to cisplatin/lipiodol. Br J Cancer 2003; 89: 1614-19.
20. Okusaka T, Okada S, Nakanishi T, Fujiyama S, Kubo Y. Phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in patients with hepatocellular carcinoma. Invest New Drugs 2004; 22: 169-76.
21. Shibata J, Fujiyama S, Sato T, Kishimoto S, Fukushima S, Nakano M. Hepatic arterial injection chemotherapy with cisplatin suspended in an oily lymphographic agent for hepatocellular carcinoma. Cancer 1989; 64: 1586-94.
22. Taguchi T, Saito T, Ota J et al. Phase I study of YM 881 (zinostatin stimalamer) suspension by hepatic arterial infusion. Jpn J Cancer Chemother 1991; 18: 1657-63.
23. Taguchi T, Saito T, Ota J et al. Phase II study of YM 881 (zinostatin stimalamer) suspension injected into the hepatic artery. Jpn J Cancer Chemother 1991; 18: 1665-75.
24. Kishimoto S, Noguchi T, Yamaoka T, Fukushima S, Takeuchi Y. In vitro release of SM-11355, cis[(1R, 2R)-1,2-Cyclohexanediamine-N,N ′)bis(Myristato)]Platinum (II) suspended in lipiodol. Biol Pharm Bull 2000; 23: 637-40.
25. Gonzalez VM, Fuertes MA, Alonso C, Perez JM. Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 2001; 59: 657-63.
26. Kartalou M, Essigmann JM. Recognition of cisplatin adducts by cellular proteins. Mutat Res 2001; 478: 1-21.
27. Hirohashi S, Shimosato Y, Kameya T et al. Production of -fetoprotein and normal serum proteins by xenotransplanted human hepatomas in relation to their growth and morphology. Cancer Res 1979; 39: 1819-28.
28. Okuska T, Okada S, Ishii H et al. Transarterial chemotherapy with zinostatin stimalamer for hepatocellular carcinoma. Oncology 1998; 55: 276-83.
29. Ikeda K, Saitoh S, Kobayashi M et al. Hepatic vascular side effects of styrene maleic acid neocarzinostatin in the treatment of hepatocellular carcinoma. J Gastroenterol 2000; 35: 353-60.